Overexpression of 11β‐hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non‐alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: The enzyme 11β‐hydroxysteroid‐dehydrogenase type 1 (11β‐HSD 1) catalyses the reactivation of intracellular cortisol. We explored the potential role of 11β‐HSD 1 overexpression in visceral adipose tissue (VAT) in non‐alcoholic fatty liver disease (NAFLD) assessing sequential changes of enzyme expression, in hepatic and adipose tissue, and the occurrence of portal hypercortisolism in obese mice. 11β‐HSD 1 expression was also assessed in tissues from obese patients undergoing bariatric surgery. Methods: Peripheral and portal corticosterone levels and liver histology were assessed in ob/ob mice at two time points (8–12 weeks of age). 11β‐HSD 1 tissue expression was assessed in by RT‐pcr in ob/ob mice and in 49 morbidly obese patients. Results: Portal corticosterone serum levels were higher in obese mice with a 26% decrease between 8 and 12 weeks of age (controls: 78.3 ± 19.7 ng/ml, 8‐week‐old ob/ob: 167.5 ± 14.5 ng/ml and 12‐week‐old ob/ob: 124.3 ± 28 ng/ml, P < 0.05). No significant differences were found in peripheral corticosterone serum levels. Expression of 11β‐HSD1 was lower in the liver [–45% at 8 weeks and –35% at 12‐weeks (P = 0.0001)] and highly overexpressed in VAT in obese mice, compared to controls (128‐fold higher in 8‐week‐old ob/ob and 41‐fold higher in 12‐week‐old ob/ob, P < 0.01). No significant differences were seen in the expression of 11β‐HSD1 in subcutaneous adipose tissue. In multivariate analysis, human 11β‐HSD1 expression in VAT (OR: 1.385 ± 1.010–1.910) was associated with NAFLD. Conclusion: Murine NAFLD is associated with portal hypercortisolism and11β‐HSD 1 overexpression in VAT. In humans, 11β‐HSD 1 VAT expression was associated with the presence of NAFLD. Thus, local corticosteroid production in VAT may contribute to NAFLD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445 · cited 1×
“Abnormal aminotransferase levels were defined as ALT > 30 IU/L in men and 19 IU/L in women (31).”
Background11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 1×
“A plausible explanation for this phenomenon is to consider the MS a result of increased local glucocorticoid activity in certain organs suggesting that central obesity might be, as proposed by Bujalska decades ago, a ‘Cushing’s disease of the omentum’ (19).”
BackgroundMacfarlane, D. P., Forbes, S., & Walker, B. R. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0054 · Cited by 385
Cited by
11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887
Ballestri, S., Nascimbeni, F., Baldelli, E., Marrazzo, A., Romagnoli, D., & Lonardo, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0556-1 · Cited by 545
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Pizarro, M., Solís, N., Quintero, P., Barrera, F., Cabrera, D., Rojas‐de Santiago, P., Arab, J. P., Padilla, O., Roa, J. C., Moshage, H., et al. (2015) · Liver International · doi:10.1111/liv.12794 · Cited by 66
“A role of glucocorticoid local activation in NAFLD related to 11b-HSD1 expression that could increase MR activation has been previously described by our group in human studies (14, 15, 36).”
BackgroundSelf-citation
Metadata
- Authors
- Candia, R., Riquelme, A., Baudrand, R., Carvajal, C. A., Morales, M., Solís, N., Pizarro, M., Escalona, A., Carrasco, G., Boza, C., Pérez, G., Padilla, O., Cerda, J., Fardella, C. E., & Arrese, M.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2011-12-04
- Volume
- 32
- Issue
- 3
- Pages
- 392-399
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2002107339
- Cited by
- 54
- References
- 5
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overexpression of 11β‐hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non‐alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1111/j.1478-3231.2011.02685.x
- The paper
- Candia, R., Riquelme, A., Baudrand, R., Carvajal, C. A., Morales, M., Solís, N., Pizarro, M., Escalona, A., Carrasco, G., Boza, C., Pérez, G., Padilla, O., Cerda, J., Fardella, C. E., & Arrese, M. (2012). Overexpression of 11β‐hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non‐alcoholic fatty liver disease. Liver International. https://doi.org/10.1111/j.1478-3231.2011.02685.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.